These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37432022)

  • 1. Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis.
    Sakellariou GT; Konsta M; Katsigianni I; Deligeorgakis D; Zisopoulos D; Vounotrypidis P
    Int J Rheum Dis; 2023 Dec; 26(12):2603-2606. PubMed ID: 37432022
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
    Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
    Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
    Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):610-617. PubMed ID: 33993905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
    Cortese A; Lucchetti R; Altobelli A; Conte A; Primavera M; Valesini G; Millefiorini E; Scrivo R
    Mult Scler Relat Disord; 2019 Oct; 35():193-195. PubMed ID: 31398658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
    Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Macaluso F; Guggino G; Ciccia F
    Clin Exp Rheumatol; 2021; 39(1):224. PubMed ID: 32452343
    [No Abstract]   [Full Text] [Related]  

  • 10. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
    Nisar MK
    Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
    [No Abstract]   [Full Text] [Related]  

  • 11. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
    N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
    Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
    Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience.
    Bulut Gökten D; Mercan R
    Clin Exp Rheumatol; 2024 Mar; 42(3):767. PubMed ID: 37877409
    [No Abstract]   [Full Text] [Related]  

  • 15. Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient.
    Durmaz K; Ataseven A; Ozer I
    Dermatol Ther; 2020 Jul; 33(4):e13504. PubMed ID: 32388886
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of secukinumab for the treatment of active ankylosing spondylitis.
    Loricera J; Galíndez-Aguirregoikoa E; Blanco R
    Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.
    Macaluso F; Guggino G; Mauro D; Rizzo C; Bignone R; Ciccia F
    Clin Exp Rheumatol; 2019; 37(6):1096. PubMed ID: 31287406
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
    Baraliakos X; Borah B; Braun J; Baeten D; Laurent D; Sieper J; Emery P; McInnes IB; van Laar JM; Wordsworth P; Wollenhaupt J; Kellner H; Colin L; Vandenhende F; Radford K; Hueber W
    Ann Rheum Dis; 2016 Feb; 75(2):408-12. PubMed ID: 26248638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
    RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.